SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated in the 2nd half of 2027Entered into a clinical trial collaboration and supply agreement with Lilly to evaluate PRT13722 in combi…

PRLD

Related stories